GSK1521498

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

AlcoholismObesity

Phase 1

GSK1521498 Alcohol Interaction Study

CompletedNCT01366573

GlaxoSmithKlineAlcoholism

Start: 2011-05-13End: 2011-09-16Updated: 2017-07-21

To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

CompletedNCT01738867

GlaxoSmithKlineAlcoholism

Start: 2012-12-12End: 2014-05-27Updated: 2017-05-10

Phase 2

A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.

CompletedNCT01195792

GlaxoSmithKlineObesity

Start: 2010-09-30End: 2011-05-31Updated: 2016-12-01